Video

Dr. Chien on Tucatinib in HER2+ Breast Cancer

Author(s):

A. Jo Chien, MD

In Partnership With:

A. Jo Chien, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of tucatinib (ONT-380) in the treatment of patients with HER2-positive breast cancer.

A. Jo Chien, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of tucatinib (ONT-380) in the treatment of patients with HER2-positive breast cancer.

Tucatinib is one of many TKIs that possesses the potential to penetrate the blood—brain barrier, says Chien. In addition to tucatinib, lapatinib (Tykerb) and neratinib (Nerlynx) have also been looked at in the treatment of patients with brain metastases. As single agents, they have not demonstrated compelling responses, but when paired with capecitabine, these agents have shown impressive responses in the central nervous system, says Chien.

Tucatinib has also shown strong responses when paired with trastuzumab (Herceptin) and capecitabine. The unique aspect of tucatinib is that it has more preferential binding to HER2 than EGFR, and therefore, has lower rates of diarrhea, explains Chien. An issue with the TKIs has been the associated gastrointestinal toxicity. If tucatinib continues to show a safety profile that is consistent with what has been observed to date, it could fulfill a large unmet need for patients.

Related Videos
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Related Content
Breast Cancer
November 13th 2024

IBI354 Shows Efficacy and Safety in HER2+ and HER2-Low Advanced Breast Cancer

Jennie W. Taylor, MD, MPH, associate professor, clinical neurology, University of California, San Francisco, community engagement liaison, Neurologic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center
October 10th 2024

FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma

Here is your snapshot of all therapeutic options that the FDA approved in October 2024.
November 5th 2024

OncLive’s October Roundup of Key FDA Approvals in Oncology

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

Hope Rugo, MD, FASCO, of UCSF Helen Diller Family Comprehensive Cancer Center
October 31st 2024

Inavolisib Regimen Approval Opens the Door for Triplet Therapies in HR+, HER2– Breast Cancer

Sung Gwe Ahn, MD, PhD
October 24th 2024

Addition of OFS to Endocrine Therapy Improves Survival in HR+, HER2+ Early Breast Cancer